Compare DoorDash Inc (DASH) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs Novo Nordisk A/S — how do they compare? DoorDash Inc trades at $188.55 (market cap $81.82B), while Novo Nordisk A/S trades at $50.29 (market cap $214.94B). The key difference: Novo Nordisk A/S is far larger — about 2.6× DoorDash Inc's market cap, and Novo Nordisk A/S pays a 3.67% dividend while DoorDash Inc pays none. Which is the better fit depends on your goals.
| DASH | NVO | |
|---|---|---|
Market Cap | $81.82B | $214.94B |
Sector | Consumer Cyclical | Health |
52-Week High | $281.74 | $71.70 |
52-Week Low | $146.60 | $35.29 |
Enterprise Value | $79.58B | $233.91B |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $189.57, down 1.17% on the day, with a bullish technical outlook supported by moving averages and key resistance near $200. The company reported strong revenue growth to $13.72B in 2025 and achieved profitability with a net income margin of 6.81%. Recent partnerships, such as with Hungry Howie's and Urban Outfitters, highlight ongoing expansion in digital commerce and loyalty programs.
The stock presents a growth opportunity with a consensus price target of $237.92, implying 25% upside, but faces risks from intense competition and high valuation multiples. Earnings momentum is mixed, with a recent beat in Q1 2026 but misses in prior quarters. Investors should weigh robust cash flow generation against elevated P/E and EV/EBITDA ratios for a balanced view.
Novo Nordisk (NVO) trades at $49.28, down 0.4% on the day, with strong technical momentum indicated by bullish moving averages and a neutral RSI near 63. The company demonstrates robust fundamentals with a P/E of 11.83, net income margin of 37.2%, and consistent earnings beats in recent quarters. Recent news highlights competitive strength in GLP-1 drugs, including Wegovy pill adoption outpacing Eli Lilly's offering.
Outlook remains positive given analyst consensus of 57.9% buy ratings and intrinsic value estimates near $90, though risks include prescription slowdown concerns and rising debt-to-asset ratios. The stock presents a growth opportunity in pharmaceuticals with manageable near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
